S&P Futures
4,134.75 +10.25 (+0.25%) Dow Futures
32,803.00 +66.00 (+0.20%) Nasdaq Futures
13,074.50 +43.00 (+0.33%) Russell 2000 Futures
1,916.60 +2.00 (+0.10%) Crude Oil
88.84 -1.66 (-1.83%) Gold
1,792.40 -1.60 (-0.09%)
Autolus Therapeutics plc (AUTL)
After hours:
Chart Events
Performance Outlook
| Previous Close | 3.3200 |
| Open | 3.2800 |
| Bid | 2.9500 x 1200 |
| Ask | 3.3000 x 1000 |
| Day's Range | 3.1500 - 3.4159 |
| 52 Week Range | 1.9600 - 7.9000 |
| Volume | |
| Avg. Volume | 161,520 |
| Market Cap | 300.002M |
| Beta (5Y Monthly) | 1.39 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.8420 |
| Earnings Date | Aug 04, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.06 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for AUTL
Related Research
- Autolus Therapeutics plcAnalyst Report: Johnson & JohnsonJohnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total revenue is generated in the United States.RatingFair ValueEconomic Moat2 days agoMorningstar
- GlobeNewswire
Autolus Therapeutics Reports Second Quarter 2022 Financial Results and Operational Progress
- Conference call to be held on August 4, 2022 at 8:30 am ET/1:30 pm BST -LONDON, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced its operational and financial results for the second quarter ended June 30, 2022. “Autolus has had a successful second quarter, with progress made across all fronts. We were awarded Regenerative Medicine Advanced Therapy (RMAT)
- GlobeNewswire
Correction - Autolus Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022
In the previous version the link to register for the conference call was incorrect – this press release contains the correct link to register for the call, and replaces the earlier version LONDON, July 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2022 financial results and operational highlights before open of U.S. mar
- GlobeNewswire
Autolus Therapeutics to Report Second Quarter 2022 Financial Results on August 4, 2022
LONDON, July 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2022 financial results and operational highlights before open of U.S. markets on Thursday, August 4, 2022. Management will host a conference call and webcast at 8:30 am ET/1:30 pm BST to discuss the company’s financial results and provide a general business upda
